Isotoosendanin [CAS 97871-44-8]

Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC50 = 6732 nM) . Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation[1][2][3].

[97871-44-8]

C30H38O11

574.62

O[C@@H](C[C@H]1OC(C)=O)[C@]([C@](C[C@H]2O)([H])[C@@]31C)(COC3O)[C@](C([C@@H]4OC(C)=O)=O)([H])[C@@]2([C@@](C5=O)([H])[C@@]4([C@@](C6=COC=C6)([H])C5)C)C

Apoptosis; JAK; STAT; TGF-β Receptor

10mM

99.51

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C (Powder, protect from light)

Blue Ice